RAP 0.00% 20.5¢ resapp health limited

Estimating NPV of ResAppDx

  1. 294 Posts.
    lightbulb Created with Sketch. 76

    Hi All,

    I love a good spreadsheet so was going to look at the NPV's associatedwith ResAppDx so I could do some sensitivities around changed input parameters both in peak year sales and revenue projections.

    In setting this up I came across the following assumptions adopted byAcuity in the financial modelling, particularly around COGS and SG&A (I hadto look up what these mean) which equate to 55% of expectedrevenues.


    Over the life of the economic modelling period (to 2041) this has apretty significant impact on cashflows and hence I am assuming valuations and has been applied to all 4 ofour products.

    Cheers


    Information from Acuity Report

    https://hotcopper.com.au/data/attachments/4587/4587243-38b5e842707035d8ffea9d6876e33a71.jpg


    https://hotcopper.com.au/data/attachments/4587/4587249-ebc523416f315deee08ac964ea0666c8.jpg
    COGs and SG&A definitions from a google search:

    https://hotcopper.com.au/data/attachments/4587/4587278-6f0248f3bf7b11d356766353f7a36c1a.jpg

    Impacts on ResAppDx cashflows (Note that I've initially adopted a discount rate of 8% with no CPI.)

    https://hotcopper.com.au/data/attachments/4587/4587283-9d2ad2681f8df1e8b505b2b64e657149.jpg


    If I was toassume $10M/ annum COGS/ SG&A associated with ResAppDx instead of 55% of revenue, this has asignificant impact on cashflows and NPV.



    https://hotcopper.com.au/data/attachments/4587/4587288-db2a3e5a55d4fc5ed25f2301dfce8516.jpg

 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.